Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...

Multiple myeloma survivor Ronald D. Chin, one of CURE’s contributing bloggers, shared a bit of his blood cancer journey in a ...

The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma.

In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...

Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...

GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...